Radiation guidelines for gliomas
Gliomas are the most frequent primary brain tumour. The proximity of organs at risk, the infiltrating nature, and the radioresistance of gliomas have to be taken into account in the choice of prescribed dose and technique of radiotherapy. The management of glioma patients is based on clinical factor...
Gespeichert in:
Veröffentlicht in: | Cancer radiothérapie 2022-02, Vol.26 (1-2), p.116-128 |
---|---|
Hauptverfasser: | , , , , , |
Format: | Artikel |
Sprache: | eng |
Schlagworte: | |
Online-Zugang: | Volltext |
Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
container_end_page | 128 |
---|---|
container_issue | 1-2 |
container_start_page | 116 |
container_title | Cancer radiothérapie |
container_volume | 26 |
creator | Antoni, D. Feuvret, L. Biau, J. Robert, C. Mazeron, J.-J. Noël, G. |
description | Gliomas are the most frequent primary brain tumour. The proximity of organs at risk, the infiltrating nature, and the radioresistance of gliomas have to be taken into account in the choice of prescribed dose and technique of radiotherapy. The management of glioma patients is based on clinical factors (age, KPS) and tumour characteristics (histology, molecular biology, tumour location), and strongly depends on available and associated treatments, such as surgery, radiation therapy, and chemotherapy. The knowledge of molecular biomarkers is currently essential, they are increasingly evolving as additional factors that facilitate diagnostics and therapeutic decision-making. We present the update of the recommendations of the French society for radiation oncology on the indications and the technical procedures for performing radiation therapy in patients with gliomas.
Les gliomes sont les tumeurs cérébrales primitives de l’adulte les plus fréquentes. La proximité des organes à risque, leur nature infiltrante et leur faible radiosensibilité sont des facteurs à prendre en compte dans le choix des doses et techniques d’irradiation. La prise en charge des patients atteints de gliomes repose sur les caractéristiques cliniques du patient, et de la tumeur (histologie, biologie moléculaire, localisation anatomique), ainsi que sur la nature des traitements disponibles et associés. La connaissance des marqueurs moléculaires tumoraux est devenue essentielle ces dernières années. La multitude de facteurs a rendu complexe les stratégies thérapeutiques pour ces patients de pronostic très variable. Les radiations constituent toujours un pilier majeur du traitement des gliomes. Nous présentons la mise à jour des recommandations de la Société française de radiothérapie oncologique sur les indications et les modalités techniques de réalisation de la radiothérapie pour les patients atteints de gliome. |
doi_str_mv | 10.1016/j.canrad.2021.08.006 |
format | Article |
fullrecord | <record><control><sourceid>proquest_hal_p</sourceid><recordid>TN_cdi_hal_primary_oai_HAL_hal_03889553v1</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><els_id>S1278321821001955</els_id><sourcerecordid>2614753638</sourcerecordid><originalsourceid>FETCH-LOGICAL-c396t-4a6130d5849bcbde64a8280bba3eac80f7acd1bd4f90490c31828e446e8cd6ee3</originalsourceid><addsrcrecordid>eNp9kE1LAzEQQIMotlb_gcge9bBrsslmk4sgRa1QEETPIZvM1pT9qMm24L83ZWuPnmaYeTPDPISuCc4IJvx-nRndeW2zHOckwyLDmJ-gKSm5TDkvxGnM81KkNCdigi5CWONIcFmcowllsqBciilK3rV1enB9l6y2zkLjOghJ3ftk1bi-1eESndW6CXB1iDP0-fz0MV-ky7eX1_njMjVU8iFlmhOKbSGYrExlgTMtcoGrSlPQRuC61MaSyrJaYiaxoSS2gTEOwlgOQGfobtz7pRu18a7V_kf12qnF41Lta5gKIYuC7khkb0d24_vvLYRBtS4YaBrdQb8NKueElfFBKiLKRtT4PgQP9XE3wWrvUa3V6FHtPSosVLQUx24OF7ZVC_Y49CcuAg8jANHJzoFXwTjoDFjnwQzK9u7_C79zfoO2</addsrcrecordid><sourcetype>Open Access Repository</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2614753638</pqid></control><display><type>article</type><title>Radiation guidelines for gliomas</title><source>MEDLINE</source><source>Elsevier ScienceDirect Journals Complete</source><creator>Antoni, D. ; Feuvret, L. ; Biau, J. ; Robert, C. ; Mazeron, J.-J. ; Noël, G.</creator><creatorcontrib>Antoni, D. ; Feuvret, L. ; Biau, J. ; Robert, C. ; Mazeron, J.-J. ; Noël, G.</creatorcontrib><description>Gliomas are the most frequent primary brain tumour. The proximity of organs at risk, the infiltrating nature, and the radioresistance of gliomas have to be taken into account in the choice of prescribed dose and technique of radiotherapy. The management of glioma patients is based on clinical factors (age, KPS) and tumour characteristics (histology, molecular biology, tumour location), and strongly depends on available and associated treatments, such as surgery, radiation therapy, and chemotherapy. The knowledge of molecular biomarkers is currently essential, they are increasingly evolving as additional factors that facilitate diagnostics and therapeutic decision-making. We present the update of the recommendations of the French society for radiation oncology on the indications and the technical procedures for performing radiation therapy in patients with gliomas.
Les gliomes sont les tumeurs cérébrales primitives de l’adulte les plus fréquentes. La proximité des organes à risque, leur nature infiltrante et leur faible radiosensibilité sont des facteurs à prendre en compte dans le choix des doses et techniques d’irradiation. La prise en charge des patients atteints de gliomes repose sur les caractéristiques cliniques du patient, et de la tumeur (histologie, biologie moléculaire, localisation anatomique), ainsi que sur la nature des traitements disponibles et associés. La connaissance des marqueurs moléculaires tumoraux est devenue essentielle ces dernières années. La multitude de facteurs a rendu complexe les stratégies thérapeutiques pour ces patients de pronostic très variable. Les radiations constituent toujours un pilier majeur du traitement des gliomes. Nous présentons la mise à jour des recommandations de la Société française de radiothérapie oncologique sur les indications et les modalités techniques de réalisation de la radiothérapie pour les patients atteints de gliome.</description><identifier>ISSN: 1278-3218</identifier><identifier>EISSN: 1769-6658</identifier><identifier>DOI: 10.1016/j.canrad.2021.08.006</identifier><identifier>PMID: 34953698</identifier><language>eng</language><publisher>France: Elsevier Masson SAS</publisher><subject>Age Factors ; Aged ; Anaplastic glioma ; Antineoplastic Agents, Alkylating ; Antineoplastic Agents, Alkylating - therapeutic use ; Biologie moléculaire ; Biomarkers ; Biomarkers, Tumor ; Biomarkers, Tumor - genetics ; Brain Neoplasms ; Brain Neoplasms - diagnostic imaging ; Brain Neoplasms - genetics ; Brain Neoplasms - pathology ; Brain Neoplasms - radiotherapy ; Cancer ; Clinical Decision-Making ; Diffuse glioma ; France ; French society for radiation oncology ; Glioblastoma ; Glioblastoma - diagnostic imaging ; Glioblastoma - radiotherapy ; Glioblastome ; Glioma ; Glioma - diagnostic imaging ; Glioma - genetics ; Glioma - pathology ; Glioma - radiotherapy ; Gliome anaplasique ; Gliome diffus ; Humans ; Karnofsky Performance Status ; Life Sciences ; Magnetic Resonance Imaging ; Middle Aged ; Neoplasm Grading ; Organs at Risk ; Radiation Oncology ; Radiation therapy ; Radiation Tolerance ; Radiothérapie ; Recommandations ; Recommendations ; Societies, Medical ; Société française de radiothérapie oncologique ; Temozolomide ; Temozolomide - therapeutic use</subject><ispartof>Cancer radiothérapie, 2022-02, Vol.26 (1-2), p.116-128</ispartof><rights>2021 Société française de radiothérapie oncologique (SFRO)</rights><rights>Copyright © 2021 Société française de radiothérapie oncologique (SFRO). Published by Elsevier Masson SAS. All rights reserved.</rights><rights>Distributed under a Creative Commons Attribution 4.0 International License</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c396t-4a6130d5849bcbde64a8280bba3eac80f7acd1bd4f90490c31828e446e8cd6ee3</citedby><cites>FETCH-LOGICAL-c396t-4a6130d5849bcbde64a8280bba3eac80f7acd1bd4f90490c31828e446e8cd6ee3</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktohtml>$$Uhttps://dx.doi.org/10.1016/j.canrad.2021.08.006$$EHTML$$P50$$Gelsevier$$H</linktohtml><link.rule.ids>230,314,780,784,885,3550,27924,27925,45995</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/34953698$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink><backlink>$$Uhttps://hal.science/hal-03889553$$DView record in HAL$$Hfree_for_read</backlink></links><search><creatorcontrib>Antoni, D.</creatorcontrib><creatorcontrib>Feuvret, L.</creatorcontrib><creatorcontrib>Biau, J.</creatorcontrib><creatorcontrib>Robert, C.</creatorcontrib><creatorcontrib>Mazeron, J.-J.</creatorcontrib><creatorcontrib>Noël, G.</creatorcontrib><title>Radiation guidelines for gliomas</title><title>Cancer radiothérapie</title><addtitle>Cancer Radiother</addtitle><description>Gliomas are the most frequent primary brain tumour. The proximity of organs at risk, the infiltrating nature, and the radioresistance of gliomas have to be taken into account in the choice of prescribed dose and technique of radiotherapy. The management of glioma patients is based on clinical factors (age, KPS) and tumour characteristics (histology, molecular biology, tumour location), and strongly depends on available and associated treatments, such as surgery, radiation therapy, and chemotherapy. The knowledge of molecular biomarkers is currently essential, they are increasingly evolving as additional factors that facilitate diagnostics and therapeutic decision-making. We present the update of the recommendations of the French society for radiation oncology on the indications and the technical procedures for performing radiation therapy in patients with gliomas.
Les gliomes sont les tumeurs cérébrales primitives de l’adulte les plus fréquentes. La proximité des organes à risque, leur nature infiltrante et leur faible radiosensibilité sont des facteurs à prendre en compte dans le choix des doses et techniques d’irradiation. La prise en charge des patients atteints de gliomes repose sur les caractéristiques cliniques du patient, et de la tumeur (histologie, biologie moléculaire, localisation anatomique), ainsi que sur la nature des traitements disponibles et associés. La connaissance des marqueurs moléculaires tumoraux est devenue essentielle ces dernières années. La multitude de facteurs a rendu complexe les stratégies thérapeutiques pour ces patients de pronostic très variable. Les radiations constituent toujours un pilier majeur du traitement des gliomes. Nous présentons la mise à jour des recommandations de la Société française de radiothérapie oncologique sur les indications et les modalités techniques de réalisation de la radiothérapie pour les patients atteints de gliome.</description><subject>Age Factors</subject><subject>Aged</subject><subject>Anaplastic glioma</subject><subject>Antineoplastic Agents, Alkylating</subject><subject>Antineoplastic Agents, Alkylating - therapeutic use</subject><subject>Biologie moléculaire</subject><subject>Biomarkers</subject><subject>Biomarkers, Tumor</subject><subject>Biomarkers, Tumor - genetics</subject><subject>Brain Neoplasms</subject><subject>Brain Neoplasms - diagnostic imaging</subject><subject>Brain Neoplasms - genetics</subject><subject>Brain Neoplasms - pathology</subject><subject>Brain Neoplasms - radiotherapy</subject><subject>Cancer</subject><subject>Clinical Decision-Making</subject><subject>Diffuse glioma</subject><subject>France</subject><subject>French society for radiation oncology</subject><subject>Glioblastoma</subject><subject>Glioblastoma - diagnostic imaging</subject><subject>Glioblastoma - radiotherapy</subject><subject>Glioblastome</subject><subject>Glioma</subject><subject>Glioma - diagnostic imaging</subject><subject>Glioma - genetics</subject><subject>Glioma - pathology</subject><subject>Glioma - radiotherapy</subject><subject>Gliome anaplasique</subject><subject>Gliome diffus</subject><subject>Humans</subject><subject>Karnofsky Performance Status</subject><subject>Life Sciences</subject><subject>Magnetic Resonance Imaging</subject><subject>Middle Aged</subject><subject>Neoplasm Grading</subject><subject>Organs at Risk</subject><subject>Radiation Oncology</subject><subject>Radiation therapy</subject><subject>Radiation Tolerance</subject><subject>Radiothérapie</subject><subject>Recommandations</subject><subject>Recommendations</subject><subject>Societies, Medical</subject><subject>Société française de radiothérapie oncologique</subject><subject>Temozolomide</subject><subject>Temozolomide - therapeutic use</subject><issn>1278-3218</issn><issn>1769-6658</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2022</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNp9kE1LAzEQQIMotlb_gcge9bBrsslmk4sgRa1QEETPIZvM1pT9qMm24L83ZWuPnmaYeTPDPISuCc4IJvx-nRndeW2zHOckwyLDmJ-gKSm5TDkvxGnM81KkNCdigi5CWONIcFmcowllsqBciilK3rV1enB9l6y2zkLjOghJ3ftk1bi-1eESndW6CXB1iDP0-fz0MV-ky7eX1_njMjVU8iFlmhOKbSGYrExlgTMtcoGrSlPQRuC61MaSyrJaYiaxoSS2gTEOwlgOQGfobtz7pRu18a7V_kf12qnF41Lta5gKIYuC7khkb0d24_vvLYRBtS4YaBrdQb8NKueElfFBKiLKRtT4PgQP9XE3wWrvUa3V6FHtPSosVLQUx24OF7ZVC_Y49CcuAg8jANHJzoFXwTjoDFjnwQzK9u7_C79zfoO2</recordid><startdate>202202</startdate><enddate>202202</enddate><creator>Antoni, D.</creator><creator>Feuvret, L.</creator><creator>Biau, J.</creator><creator>Robert, C.</creator><creator>Mazeron, J.-J.</creator><creator>Noël, G.</creator><general>Elsevier Masson SAS</general><general>Elsevier Masson</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope><scope>1XC</scope></search><sort><creationdate>202202</creationdate><title>Radiation guidelines for gliomas</title><author>Antoni, D. ; Feuvret, L. ; Biau, J. ; Robert, C. ; Mazeron, J.-J. ; Noël, G.</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c396t-4a6130d5849bcbde64a8280bba3eac80f7acd1bd4f90490c31828e446e8cd6ee3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2022</creationdate><topic>Age Factors</topic><topic>Aged</topic><topic>Anaplastic glioma</topic><topic>Antineoplastic Agents, Alkylating</topic><topic>Antineoplastic Agents, Alkylating - therapeutic use</topic><topic>Biologie moléculaire</topic><topic>Biomarkers</topic><topic>Biomarkers, Tumor</topic><topic>Biomarkers, Tumor - genetics</topic><topic>Brain Neoplasms</topic><topic>Brain Neoplasms - diagnostic imaging</topic><topic>Brain Neoplasms - genetics</topic><topic>Brain Neoplasms - pathology</topic><topic>Brain Neoplasms - radiotherapy</topic><topic>Cancer</topic><topic>Clinical Decision-Making</topic><topic>Diffuse glioma</topic><topic>France</topic><topic>French society for radiation oncology</topic><topic>Glioblastoma</topic><topic>Glioblastoma - diagnostic imaging</topic><topic>Glioblastoma - radiotherapy</topic><topic>Glioblastome</topic><topic>Glioma</topic><topic>Glioma - diagnostic imaging</topic><topic>Glioma - genetics</topic><topic>Glioma - pathology</topic><topic>Glioma - radiotherapy</topic><topic>Gliome anaplasique</topic><topic>Gliome diffus</topic><topic>Humans</topic><topic>Karnofsky Performance Status</topic><topic>Life Sciences</topic><topic>Magnetic Resonance Imaging</topic><topic>Middle Aged</topic><topic>Neoplasm Grading</topic><topic>Organs at Risk</topic><topic>Radiation Oncology</topic><topic>Radiation therapy</topic><topic>Radiation Tolerance</topic><topic>Radiothérapie</topic><topic>Recommandations</topic><topic>Recommendations</topic><topic>Societies, Medical</topic><topic>Société française de radiothérapie oncologique</topic><topic>Temozolomide</topic><topic>Temozolomide - therapeutic use</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Antoni, D.</creatorcontrib><creatorcontrib>Feuvret, L.</creatorcontrib><creatorcontrib>Biau, J.</creatorcontrib><creatorcontrib>Robert, C.</creatorcontrib><creatorcontrib>Mazeron, J.-J.</creatorcontrib><creatorcontrib>Noël, G.</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><collection>Hyper Article en Ligne (HAL)</collection><jtitle>Cancer radiothérapie</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Antoni, D.</au><au>Feuvret, L.</au><au>Biau, J.</au><au>Robert, C.</au><au>Mazeron, J.-J.</au><au>Noël, G.</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Radiation guidelines for gliomas</atitle><jtitle>Cancer radiothérapie</jtitle><addtitle>Cancer Radiother</addtitle><date>2022-02</date><risdate>2022</risdate><volume>26</volume><issue>1-2</issue><spage>116</spage><epage>128</epage><pages>116-128</pages><issn>1278-3218</issn><eissn>1769-6658</eissn><abstract>Gliomas are the most frequent primary brain tumour. The proximity of organs at risk, the infiltrating nature, and the radioresistance of gliomas have to be taken into account in the choice of prescribed dose and technique of radiotherapy. The management of glioma patients is based on clinical factors (age, KPS) and tumour characteristics (histology, molecular biology, tumour location), and strongly depends on available and associated treatments, such as surgery, radiation therapy, and chemotherapy. The knowledge of molecular biomarkers is currently essential, they are increasingly evolving as additional factors that facilitate diagnostics and therapeutic decision-making. We present the update of the recommendations of the French society for radiation oncology on the indications and the technical procedures for performing radiation therapy in patients with gliomas.
Les gliomes sont les tumeurs cérébrales primitives de l’adulte les plus fréquentes. La proximité des organes à risque, leur nature infiltrante et leur faible radiosensibilité sont des facteurs à prendre en compte dans le choix des doses et techniques d’irradiation. La prise en charge des patients atteints de gliomes repose sur les caractéristiques cliniques du patient, et de la tumeur (histologie, biologie moléculaire, localisation anatomique), ainsi que sur la nature des traitements disponibles et associés. La connaissance des marqueurs moléculaires tumoraux est devenue essentielle ces dernières années. La multitude de facteurs a rendu complexe les stratégies thérapeutiques pour ces patients de pronostic très variable. Les radiations constituent toujours un pilier majeur du traitement des gliomes. Nous présentons la mise à jour des recommandations de la Société française de radiothérapie oncologique sur les indications et les modalités techniques de réalisation de la radiothérapie pour les patients atteints de gliome.</abstract><cop>France</cop><pub>Elsevier Masson SAS</pub><pmid>34953698</pmid><doi>10.1016/j.canrad.2021.08.006</doi><tpages>13</tpages></addata></record> |
fulltext | fulltext |
identifier | ISSN: 1278-3218 |
ispartof | Cancer radiothérapie, 2022-02, Vol.26 (1-2), p.116-128 |
issn | 1278-3218 1769-6658 |
language | eng |
recordid | cdi_hal_primary_oai_HAL_hal_03889553v1 |
source | MEDLINE; Elsevier ScienceDirect Journals Complete |
subjects | Age Factors Aged Anaplastic glioma Antineoplastic Agents, Alkylating Antineoplastic Agents, Alkylating - therapeutic use Biologie moléculaire Biomarkers Biomarkers, Tumor Biomarkers, Tumor - genetics Brain Neoplasms Brain Neoplasms - diagnostic imaging Brain Neoplasms - genetics Brain Neoplasms - pathology Brain Neoplasms - radiotherapy Cancer Clinical Decision-Making Diffuse glioma France French society for radiation oncology Glioblastoma Glioblastoma - diagnostic imaging Glioblastoma - radiotherapy Glioblastome Glioma Glioma - diagnostic imaging Glioma - genetics Glioma - pathology Glioma - radiotherapy Gliome anaplasique Gliome diffus Humans Karnofsky Performance Status Life Sciences Magnetic Resonance Imaging Middle Aged Neoplasm Grading Organs at Risk Radiation Oncology Radiation therapy Radiation Tolerance Radiothérapie Recommandations Recommendations Societies, Medical Société française de radiothérapie oncologique Temozolomide Temozolomide - therapeutic use |
title | Radiation guidelines for gliomas |
url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-01T21%3A29%3A29IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_hal_p&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Radiation%20guidelines%20for%20gliomas&rft.jtitle=Cancer%20radioth%C3%A9rapie&rft.au=Antoni,%20D.&rft.date=2022-02&rft.volume=26&rft.issue=1-2&rft.spage=116&rft.epage=128&rft.pages=116-128&rft.issn=1278-3218&rft.eissn=1769-6658&rft_id=info:doi/10.1016/j.canrad.2021.08.006&rft_dat=%3Cproquest_hal_p%3E2614753638%3C/proquest_hal_p%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=2614753638&rft_id=info:pmid/34953698&rft_els_id=S1278321821001955&rfr_iscdi=true |